Xencor | Brutto Fortjeneste På Salg



Gross Profit On Sales Endring Dato
AbbVie USD 10.71B 458M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Amgen USD 5.97B 781M 2024-12
Arrowhead Research -173085000 2.55M 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Biogen USD 1.87B 44.1M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Cytokinetics -160545000 81.19M 2024-09
GlaxoSmithKline GBP 5.56B 57M 2024-12
J&J USD 15.41B 102M 2024-12
MacroGenics USD 108.84M 100.86M 2024-09
Merck USD 11.92B 852M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 12.11B 718M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Xencor -45143000 40.69M 2024-09



Xencor Brutto Fortjeneste På Salg - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.